DelveInsight Evaluates a Robust
Alzheimer's Disease
Pipeline as 150+ Influential Pharma Players to Set Foot in the Domain

2023-02-27
PRNewswire
临床结果临床3期临床1期并购
LAS VEGAS, Feb. 27, 2023 /PRNewswire/ --
The prevalence of
Alzheimer's disease
has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of
Alzheimer's disease
and the growing research and development activities to develop novel therapies to treat
Alzheimer's disease
to drive the market. The companies developing the potential therapies in the last stage of development include Eli Lilly and Company, AB Sciences, AZTherapies, and several others.
DelveInsight's
'
Alzheimer's Disease
Pipeline Insight – 2023
' report provides comprehensive global coverage of available, marketed, and pipeline
Alzheimer's disease
therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the
Alzheimer's disease
pipeline domain.
Key Takeaways from the
Alzheimer's Disease
Pipeline Report
DelveInsight's
Alzheimer's disease
pipeline report depicts a robust space with
150+ active players working to develop
160+ pipeline therapies for
Alzheimer's disease
treatment.
Key
Alzheimer's disease
companies such as
Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,  Otsuka Pharmaceutical Co., Ltd.,  Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd.,  Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., and others are evaluating new Alzheimer's disease drugs to improve the treatment landscape.
Promising
Alzheimer's disease
pipeline therapies in various stages of development include
ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002, CMS121,  LX1001,  TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx,   Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916,  AR1001, ORY-2001, LY3372689, MW150,  EX039, SLS-005,  Seltorexant, Donanemab,  SHR-1707, REM0046127,  ALZ-101, VT301, NE3107, PRX005, MK-6240,  and others.
In
February 2023,
Lantheus Holdings, Inc. announced it had
acquired Knoxville-based
MK-6240, a second-generation F 18-labeled positron emission tomography ("PET") imaging agent that targets Tau tangles in
Alzheimer's disease
.Under the terms of the agreement, Lantheus will pay an upfront payment and potential additional development and commercial milestone payments. Additionally, Lantheus will pay double-digit royalty payments for research revenue and commercial sales.
In
January 2023,
Prothena Corporation plc announced positive topline
Phase I single ascending dose (SAD) study results for
PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of
Alzheimer's disease
that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of
tau
and targets both 3R and 4R tau isoforms. The results of the study found all three dose level cohorts of PRX005 to be generally safe and well tolerated, meeting the Phase 1 SAD study primary objective. None of the treatment emergent adverse events (TEAE) were serious. No clinically relevant changes were observed in other safety parameters. PRX005 also met key pharmacokinetic (PK) and immunogenicity secondary endpoints.
In
January 2023,
Eli Lilly and Company announced the
complete response letter for the accelerated approval submission of
donanemab for the treatment of early symptomatic
Alzheimer's disease
due to the limited number of patients with at least 12 months of drug exposure data provided in the submission. No other deficiencies in the application were noted.The confirmatory Phase 3 TRAILBLAZER-ALZ 2 trial remains ongoing, with topline data read-out expected in Q2 2023, and will form the basis of donanemab's application for traditional approval shortly thereafter. Lilly will continue to work with the FDA to evaluate the fastest pathway to make this potential treatment option widely available to patients.
In
January 2023,
Coya Therapeutics, Inc. announced the recent publication of an article entitled "Ex vivo expanded human regulatory T cells modify
neuroinflammation
in a preclinical model of
Alzheimer's Disease
" in the peer-reviewed journal Acta Neuropathologica Communications.Furthermore, Treg-treated mice showed a significant reduction in total and plaque-associated microglia as well as reactive astrocytes in the dentate gyrus and frontal cortex versus untreated mice. The reduction in the number of plaque-associated glial cells and suppression of pro-inflammatory signaling pathways within these cells following Treg therapy may attenuate the contribution of these toxic glial cells in
AD
pathology resulting in mitigation of amyloid burden.
In
November 2022,
Eli Lilly and Company announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the
Phase III TRAILBLAZER-ALZ 4 study, providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic
Alzheimer's disease
treated with amyloid-targeting therapies. Donanemab is an investigational antibody that targets a modified form of beta-amyloid plaque called N3pG.
Request a sample and discover the recent advances in
Alzheimer's disease
drug treatment @
Alzheimer's Disease
Pipeline Report
The
Alzheimer's disease
pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage
Alzheimer's disease
drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the
Alzheimer's disease
clinical trial landscape.
Alzheimer's Disease
Overview
Alzheimer's disease (AD)
is a slowly progressive
brain disease
that manifests itself many years before symptoms appear. It is the leading cause of
dementia
, accounting for 60% to 80% of cases. The accumulation of the protein fragment beta-amyloid (plaques) outside neurons in the brain and twisted strands of the protein
tau
(tangles) inside neurons are the hallmark pathologies of
Alzheimer's disease
.
Alzheimer's disease
is a progressive disease, so the symptoms worsen over time.
Memory loss
is a key feature, and it is often one of the first
Alzheimer's disease
symptoms to appear. The other
Alzheimer's disease
symptoms include
cognitive deficits
, problems with recognition, problems with spatial awareness, and others.
A thorough clinical evaluation, a detailed patient history, and various specialized tests are used to make an
Alzheimer's disease
diagnosis. Clinical diagnosis, which is usually made during the early stages of the disease, lumbar puncture, and imaging studies are all methods of diagnosing
Alzheimer's disease
.
Treatment for
Alzheimer's disease
includes options that may alleviate symptoms and improve quality of life. To treat cognitive symptoms, the FDA has approved two types of medications to treat cognitive symptoms: cholinesterase inhibitors
cholinesterase
inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda). Other non-pharmacological therapies are also used to maintain or improve cognitive function, daily living ability, or overall quality of life.
Find out more about drugs for
Alzheimer's disease
@
New
Alzheimer's Disease
Drugs
A snapshot of the
Alzheimer's Disease
Pipeline Drugs mentioned in the report:
Learn more about the emerging
Alzheimer's disease
pipeline therapies @
Alzheimer's Disease
Clinical Trials
Alzheimer's Disease
Therapeutics Assessment
The
Alzheimer's disease
pipeline report proffers an integral view of
Alzheimer's disease
emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the
Alzheimer's Disease
Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment
By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
Therapeutics Assessment
By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
Therapeutics Assessment
By Mechanism of Action: Amyloid beta-protein inhibitors, Inflammation mediator inhibitors, Immunostimulants,
Tumour necrosis factor alpha
inhibitors, Microfilament protein modulators, Angiogenesis inhibitors,
Colony stimulating factor
inhibitors,
Coronavirus-3C-like-proteinase
inhibitors, Endopeptidase Clp inhibitors, Focal adhesion protein-tyrosine kinase inhibitors,
Lyn protein-tyrosine kinase
inhibitors, Macrophage colony-stimulating factor receptor modulators, Mast cell inhibitors,
Platelet-derived growth factor receptor
antagonists, Protein tyrosine kinase inhibitors, Proto oncogene protein c-kit inhibitors, Proto-oncogene protein c-fyn modulators, Type 3 fibroblast growth factor receptor antagonists
Key Alzheimer's Disease Companies: Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,  Otsuka Pharmaceutical Co., Ltd.,  Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd.,  Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., and others.
Key
Alzheimer's Disease
Pipeline Therapies: ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002,CMS121,  LX1001,  TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx,   Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916,  AR1001, ORY-2001, LY3372689, MW150,  EX039, SLS-005,  Seltorexant, Donanemab,  SHR-1707, REM0046127,  ALZ-101, VT301, NE3107, PRX005, MK-6240, and others.
Dive deep into rich insights for new drugs for
Alzheimer's disease
treatment; visit @
Alzheimer's Disease
Medications
Table of Contents
For further information on the
Alzheimer's disease
 pipeline therapeutics, reach out @
Alzheimer's Disease
 Drug Treatment
Related Reports
Alzheimer's Disease
Epidemiology
Alzheimer's Disease
 Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted
Alzheimer's disease
 epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Alzheimer's Disease
Market
Alzheimer's Disease
 Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key
Alzheimer's disease
 companies including
Neurostimulation Devices Market
Neurostimulation Devices
Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neurostimulation devices companies, including
Deep Brain Stimulation Devices Market
Deep Brain Stimulation Devices
Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key deep brain stimulation devices companies, including
Abbott, Medtronic, Boston Scientific Corporation, ALEVA NEUROTHERAPEUTICS SA., Newronika S.p.A., among others.
Neuromodulation Devices Market
Neuromodulation Devices
Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neuromodulation devices companies, including
Neuroprosthetics Market
Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neuroprosthetics companies, including
Other Trending Reports
Tay-sachs Disease
Or Gm2 Gangliosidosis Market
| Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced
Peripheral Neuropathy
Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | 
Helicobacter Pylori Infections
Market | Ophthalmic Imaging Equipment Market | 
Androgenetic Alopecia
Market | 
Allergic Rhinitis
Market | 
Chronic Inflammatory Demyelinating Polyneuropathy
Market | 
Chronic Inflammtory Demyelinating Polyneuropathy
Market | 
Colorectal Cancer
Crc Market | 
Opioid Induced Constipation
Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market
| Egfr
Non-small Cell Lung Cancer
Market | 
Helicobacter Pylori Infection
Market | 
Hyperkalemia
Market | Polycythemia Market Neurostimulation Devices Market | 
Carpal Tunnel Syndrome
Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | 
Exocrine Pancreatic Insufficiency
Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market |
Lung Fibrosis
Market |
Anterior Uveitis
Market | 22q11.2 deletion syndrome Market |
X-Linked Retinitis Pigmentosa (XLRP)
Market |
Acute Radiation Syndrome
Market | Alpha-1 Protease Inhibitor Deficiency Market |
Androgenetic Alopecia
Market | Hyperlipidemia Market | Cardiotoxicity Market |
Hypertrophic Cardiomyopathy
Market |
Fatty Acid Oxidation Disorders
(FAODs) Market |
Androgen Insensitivity Syndrome
Market | Emphysema Market | Canaloplasty Market |
Dravet Syndrome
Market |
Celiac Disease
Market |
Chlamydia Infections
Market |
Syphilis
Market |
Renal Tubular Acidosis
Market |
Palmoplantar Pustulosis
(PPP) Market |
Aplastic Anemia
Market |
Bacterial Pneumonia
Market |
B cell Chronic Lymphocytic Leukemia
Market | B cell
Lymphomas
Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 |
Glioblastoma
Market
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Additionally, get in touch with our business executive to explore @
Healthcare Due Diligence Services
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
阿尔茨海默病,肥大型心肌病,B细胞慢性淋巴细胞白血病
[+33]
靶点
TAU,Cholinesterase,TNF-α
[+4]
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。